Dutasteride Capsule, Liquid Filled
Product Images NDC 68071-3857

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Dutasteride (NDC 68071-3857). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3857 9)

This is a product label for pharmaceuticals from a company named "re Pharmaceuticals, Inc." The text includes details such as product codes, lot numbers, expiration dates, and dosage information for Dutasteride Capsules. It also contains warnings about keeping the product out of reach of children and storing it at a controlled temperature range of 68-77°F. For medical advice or reporting side effects, it advises contacting a doctor or the FDA.*

FDA Label Image

Figure-1 (Figure 1)

This text seems to contain information related to a medical treatment involving a placebo and dutasteride, lasting for 12 months. The numbers "18" and "24" may refer to specific data points within the treatment regimen. Overall, it seems to be a clinical treatment record.*

FDA Label Image

Figure-2 (Figure 2)

This text provides information on the percentage of patients in different groups at specific time points during a treatment study. It shows the number of events and the number of patients at risk in both the placebo group and the dutasteride group over a period of 24 months. The data allows for an analysis of patient outcomes and treatment effectiveness between the two groups.*

FDA Label Image

Figure-3 (Figure 3)

This text seems to be a data table presenting the results of a study comparing the outcomes between a placebo group and a group treated with Dutasteride over a period of 24 months. It shows the number of events cumulatively observed at different time points and the number of patients at risk in each group. The table provides a visual representation of how the treatment groups compare in terms of patient outcomes over time.*

FDA Label Image

Figure-4 (Figure 4)

This text provides an overview of the mean percent change from baseline in a study involving placebo and dutasteride treatments over different months of treatment. It compares the effects on a sample size of individuals for each treatment group.*

FDA Label Image

Figure-5 (Figure 5)

This is a chart showing the mean change from baseline (in mL/sec) over different months of treatment comparing a placebo group with a Dutasteride group. The number of participants in each group is also provided for each timepoint.*

FDA Label Image

Figure-6 (Figure 6)

This text appears to provide information about different treatments involving Dutasteride, tamsulosin, and their combinations, with reference to the number of subjects involved in each treatment group. The treatments and their corresponding number of subjects are as follows: - A Dutasteride + tamsulosin: 1,575 subjects - Dutasteride 0.5 mg: 1,592 subjects - Tamsulosin 0.4 mg: 1,582 subjects Additionally, the text includes a scale labeled in months of treatment from 0 to 48.*

FDA Label Image

Figure-7 (Figure 7)

This text appears to show a comparison of different treatments with their number of patients involved at different stages of treatment. The treatments mentioned are Dutasteride, tamsulosin, and their combination. The number of patients at each stage may vary, which can provide insight into the effectiveness and popularity of the treatments.*

FDA Label Image

Structural-formula (Image 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.